BJMO - , issue ,
S. Aspeslagh , V. Kruse MD, PhD, E. De Langhe , P. Jacques , O. Malaise , D. Elewaut , B. Lauwerys , R. Wittoek , Y. Piette , B. Neyns MD, PhD
Immunotherapy has become a standard of care for patients with many different advanced solid tumors. However, boosting the immune system can induce immune related side effects, referred to as “immune-related adverse events” (irAEs). Because oncologists are not always familiar with these inflammatory autoimmune syndromes, the BSMO immunotaskforce has launched the immunomanager website which summarizes the treatment options for the most frequent irAEs including endocrine (e.g. hypo- and hyperthyroidism), digestive (e.g. colitis), pneumological (e.g. pneumonitis), dermatological and other types of irAEs. In the near future, the BSMO immunotaskforce plans to review these recommendations with Belgian organ specialists and their associations. We believe that through collaborations between organ specialists and oncologists we will be able to establish better recommendations, resulting in a better outcome for cancer patients who develop an irAE during immunotherapy.
Read moreBJMO - volume 12, issue 9, february 2018
S. Aspeslagh , V. Kruse MD, PhD, E. De Langhe , P. Jacques , O. Malaise , D. Elewaut , B. Lauwerys , R. Wittoek , Y. Piette , B. Neyns MD, PhD
Immunotherapy has become a standard of care for patients with many different advanced solid tumors. However, boosting the immune system can induce immune related side effects, referred to as “immune-related adverse events” (irAEs). Because oncologists are not always familiar with these inflammatory autoimmune syndromes, the BSMO immunotaskforce has launched the immunomanager website which summarizes the treatment options for the most frequent irAEs including endocrine (e.g. hypo- and hyperthyroidism), digestive (e.g. colitis), pneumological (e.g. pneumonitis), dermatological and other types of irAEs. In the near future, the BSMO immunotaskforce plans to review these recommendations with Belgian organ specialists and their associations. We believe that through collaborations between organ specialists and oncologists we will be able to establish better recommendations, resulting in a better outcome for cancer patients who develop an irAE during immunotherapy.
Read moreBJMO - volume 12, issue 3, february 2018
S. Aspeslagh
BJMO - volume 12, issue 3, february 2018
X. Wang , Georges El Hachem , W. Bekolo , Lissandra Dal Lago , A. Georgala MD, T. Pepersack , S. Aspeslagh , Laurence Buisseret , T. Gil MD, A. Awada MD, PhD
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
